secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2023-05-16T23:59:59+00:00
Accession:  0001104659-23-061465
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure sells portion of HEMGENIX royalty rights for up to $400M cash; runway extended to Q2 2026
--------------------------------------------------------------------------------

- Receives $375M upfront from HealthCare Royalty and Sagard Healthcare for lowest royalty tier on HEMGENIX net sales.
- Eligible for $25M milestone if 2024 HEMGENIX net sales exceed pre-specified threshold.
- Purchaser's capped return up to 1.85x purchase price (2.25x if cap not met by 2032) through 2038.
- Retains rights to other royalties and future milestones from CSL Behring totaling up to $1.5B.
- Hercules loan amended: maturity extended to Jan 5, 2027; $1.25M fee; cash runway now into Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465923061465/0001104659-23-061465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465923061465/tm2315929d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-061465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer